aminolevulinic acid has been researched along with Psoriasis in 37 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in ALA-PDT in patients with psoriasis." | 9.12 | A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. ( Gerritsen, MJ; Kleinpenning, MM; Smits, T; van de Kerkhof, PC; van Erp, PE, 2006) |
| "We first set up imiquimod-induced dermatitis in mice that closely resembles human psoriasis lesions." | 7.81 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "We established the topical delivery profiles of anti-psoriatic drugs via imiquimod-treated psoriasis-like skin." | 7.81 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "Psoriasis lesions accumulate protoporphyrin IX (PpIX) with a variable distribution within plaques due to variations in hyperkeratosis causing differences in penetration of cream or light." | 7.76 | The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis. ( Gerritsen, RM; Kanis, JH; Kleinpenning, MM; Smits, T; van de Kerkhof, P; van Erp, PE, 2010) |
| " This paper describes the accumulation of the photosensitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emission induced by low-intensity laser excitation at 488 nm." | 7.69 | The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. ( Collins, P; Robinson, DJ; Sheehan-Dare, RA; Stables, GI; Stringer, MR, 1996) |
| "Tacrolimus flux was enhanced from 2 to 21 μg/cm2/h by imiquimod intervention." | 5.42 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "Psoriasis is a chronic inflammatory skin disease and topical therapy remains a key role for treatment." | 5.42 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "To study the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in ALA-PDT in patients with psoriasis." | 5.12 | A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. ( Gerritsen, MJ; Kleinpenning, MM; Smits, T; van de Kerkhof, PC; van Erp, PE, 2006) |
| "Photodynamic therapy for psoriasis showed promise in the early 1990s with reports of plaque clearance following topical aminolevulinic acid - photodynamic therapy (ALA-PDT)." | 4.91 | Photodynamic therapy for psoriasis. ( Adelzadeh, L; Choi, YM; Wu, JJ, 2015) |
| "We have reviewed the results of clinical investigations into the use of photodynamic therapy (PDT) with intravenous injection of hematoporphyrin derivative (HpD), Photofrin (PF) and Sn-protoporphyrin (Sn-Pp) or oral administration of delta-aminolevulinic acid in the treatment of skin cancers and/or psoriasis." | 4.79 | Photodynamic therapy with systemic administration of photosensitizers in dermatology. ( Calzavara-Pinton, PG; Ortel, B; Szeimies, RM; Zane, C, 1996) |
| "In this study, we first revealed that ALA-PDT treatment effectively ameliorated the psoriasis-like lesion in imiquimod (IMQ)-induced mouse model and further explored the potential molecular mechanism and related signalling pathways during the treatment." | 3.91 | ALA-PDT alleviates the psoriasis by inhibiting JAK signalling pathway. ( Chen, X; Fang, F; Yi, F; Zhang, J; Zheng, X; Zhou, B, 2019) |
| "We first set up imiquimod-induced dermatitis in mice that closely resembles human psoriasis lesions." | 3.81 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "We established the topical delivery profiles of anti-psoriatic drugs via imiquimod-treated psoriasis-like skin." | 3.81 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "To observe the efficacy of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for treating psoriasis vulgaris in guinea pigs." | 3.77 | [Therapeutic effect of photodynamic treatment for psoriasis vulgaris in guinea pigs]. ( Duan, SJ; Li, KY; Liu, HW; Xie, GH, 2011) |
| "Psoriasis lesions accumulate protoporphyrin IX (PpIX) with a variable distribution within plaques due to variations in hyperkeratosis causing differences in penetration of cream or light." | 3.76 | The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis. ( Gerritsen, RM; Kanis, JH; Kleinpenning, MM; Smits, T; van de Kerkhof, P; van Erp, PE, 2010) |
| "Psoriasis has been shown to highly accumulate protoporphyrin IX (PpIX), but a variable distribution within plaques after fluorescence diagnosis is seen." | 3.73 | Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. ( Ewalds, E; Gerritsen, MJ; Kleinpenning, MM; Smits, T; van de Kerkhof, PC; van Erp, PE, 2006) |
| "Photodynamic therapy (PDT) with topical aminolevulinic acid (ALA) has been shown in previous studies to improve psoriasis." | 3.71 | Oral aminolevulinic acid induces protoporphyrin IX fluorescence in psoriatic plaques and peripheral blood cells. ( Bissonnette, R; Korbelik, M; Lui, H; McLean, DI; Zeng, H, 2001) |
| " This paper describes the accumulation of the photosensitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emission induced by low-intensity laser excitation at 488 nm." | 3.69 | The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. ( Collins, P; Robinson, DJ; Sheehan-Dare, RA; Stables, GI; Stringer, MR, 1996) |
| "We report a case of psoriasis reactivation following photodynamic therapy with delta-aminolevulinic acid." | 3.69 | Købner reaction induced by photodynamic therapy using delta-aminolevulinic acid. A case report. ( Stender, IM; Wulf, HC, 1996) |
| "Its use in the treatment of psoriasis has been attempted only quite recently and some modest success achieved." | 2.39 | Photodynamic therapy for psoriasis? ( Fergin, P, 1996) |
| "Bowen's disease was highly responsive, provided that adequate light and HpD or PF doses were delivered." | 2.39 | Photodynamic therapy with systemic administration of photosensitizers in dermatology. ( Calzavara-Pinton, PG; Ortel, B; Szeimies, RM; Zane, C, 1996) |
| "In spite of significant advances in the treatment of psoriasis, more effective and safer therapeutic strategies are still needed." | 1.46 | Systemic ALA-PDT effectively blocks the development of psoriasis-like lesions and alleviates leucocyte infiltration in the K14-VEGF transgenic mouse. ( Chen, T; Fu, LX; Guo, ZP; Liu, XY; Wu, YB; Zhang, LW, 2017) |
| "Psoriasis is one of the most common immune-mediated chronic inflammatory skin disorders." | 1.46 | Systemic ALA-PDT effectively blocks the development of psoriasis-like lesions and alleviates leucocyte infiltration in the K14-VEGF transgenic mouse. ( Chen, T; Fu, LX; Guo, ZP; Liu, XY; Wu, YB; Zhang, LW, 2017) |
| "Psoriasis is a chronic inflammatory skin disorder that greatly affects the patient's quality of life." | 1.46 | Photodynamic therapy with 5-aminolevulinic acid suppresses IFN-γ-induced K17 expression in HaCaT cells via MAPK pathway. ( Sun, Q; Wang, XL, 2017) |
| "Tacrolimus flux was enhanced from 2 to 21 μg/cm2/h by imiquimod intervention." | 1.42 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "Psoriasis is a chronic inflammatory skin disease and topical therapy remains a key role for treatment." | 1.42 | Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. ( Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH, 2015) |
| "PDL seems to be effective in the treatment of nail psoriasis and improves nail matrix and nail bed involvement." | 1.35 | Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. ( Fernández-Guarino, M; García-Morales, I; Harto, A; Jaén, P; Sánchez-Ronco, M, 2009) |
| "Nail psoriasis is often refractory to traditional treatments, and patients with nail psoriasis usually demand a therapeutic option." | 1.35 | Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. ( Fernández-Guarino, M; García-Morales, I; Harto, A; Jaén, P; Sánchez-Ronco, M, 2009) |
| "Psoriasis has been shown to highly accumulate protoporphyrin IX (PpIX), but a variable distribution within plaques after fluorescence diagnosis is seen." | 1.33 | Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. ( Ewalds, E; Gerritsen, MJ; Kleinpenning, MM; Smits, T; van de Kerkhof, PC; van Erp, PE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (24.32) | 18.2507 |
| 2000's | 17 (45.95) | 29.6817 |
| 2010's | 10 (27.03) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T | 1 |
| Zhang, LW | 1 |
| Fu, LX | 1 |
| Wu, YB | 1 |
| Liu, XY | 1 |
| Guo, ZP | 1 |
| Wen, X | 1 |
| Li, Y | 1 |
| Hamblin, MR | 1 |
| Wang, XL | 1 |
| Sun, Q | 1 |
| Yi, F | 1 |
| Zheng, X | 1 |
| Fang, F | 1 |
| Zhang, J | 1 |
| Zhou, B | 1 |
| Chen, X | 1 |
| Choi, YM | 1 |
| Adelzadeh, L | 1 |
| Wu, JJ | 1 |
| Lin, YK | 1 |
| Yang, SH | 1 |
| Chen, CC | 1 |
| Kao, HC | 1 |
| Fang, JY | 1 |
| Shokeen, D | 1 |
| Smits, T | 5 |
| van Laarhoven, AI | 1 |
| Staassen, A | 1 |
| van de Kerkhof, PC | 4 |
| van Erp, PE | 5 |
| Gerritsen, MJ | 4 |
| Fernández-Guarino, M | 1 |
| Harto, A | 1 |
| Sánchez-Ronco, M | 1 |
| García-Morales, I | 1 |
| Jaén, P | 1 |
| Fang, YP | 1 |
| Huang, YB | 1 |
| Wu, PC | 1 |
| Tsai, YH | 1 |
| Kleinpenning, MM | 3 |
| Kanis, JH | 1 |
| van de Kerkhof, P | 1 |
| Gerritsen, RM | 1 |
| Xie, GH | 1 |
| Li, KY | 1 |
| Liu, HW | 1 |
| Duan, SJ | 1 |
| Lee, Y | 1 |
| Baron, ED | 1 |
| Bissonnette, R | 2 |
| Tremblay, JF | 1 |
| Juzenas, P | 1 |
| Boushira, M | 1 |
| Lui, H | 2 |
| Beattie, PE | 1 |
| Dawe, RS | 1 |
| Ferguson, J | 1 |
| Ibbotson, SH | 2 |
| Radakovic-Fijan, S | 2 |
| Blecha-Thalhammer, U | 1 |
| Schleyer, V | 2 |
| Szeimies, RM | 4 |
| Zwingers, T | 2 |
| Hönigsmann, H | 1 |
| Tanew, A | 2 |
| Fergin, P | 2 |
| Robles, CA | 1 |
| Yim, YC | 1 |
| Lee, ES | 2 |
| Chung, PS | 1 |
| Rhee, CK | 1 |
| Fransson, J | 1 |
| Ros, AM | 1 |
| Karrer, S | 2 |
| Landthaler, M | 2 |
| Ewalds, E | 1 |
| Kim, JY | 1 |
| Kang, HY | 1 |
| Kim, YC | 1 |
| Boehncke, WH | 1 |
| Sterry, W | 1 |
| Kaufmann, R | 1 |
| Stringer, MR | 3 |
| Collins, P | 3 |
| Robinson, DJ | 3 |
| Stables, GI | 3 |
| Sheehan-Dare, RA | 3 |
| Stender, IM | 1 |
| Wulf, HC | 1 |
| Calzavara-Pinton, PG | 1 |
| Ortel, B | 1 |
| Zane, C | 1 |
| Wang, I | 1 |
| Andersson-Engels, S | 1 |
| Nilsson, GE | 1 |
| Wårdell, K | 1 |
| Svanberg, K | 1 |
| Fritsch, C | 1 |
| Lehmann, P | 1 |
| Stahl, W | 1 |
| Schulte, KW | 1 |
| Blohm, E | 1 |
| Lang, K | 1 |
| Sies, H | 1 |
| Ruzicka, T | 1 |
| Vernon, DI | 1 |
| Brown, SB | 1 |
| Zeng, H | 1 |
| McLean, DI | 1 |
| Korbelik, M | 1 |
| Wang, Y | 1 |
| Fu, S | 1 |
| Lu, Y | 1 |
| Lai, R | 1 |
| Liu, Z | 1 |
| Luo, W | 1 |
| Xu, Y | 1 |
9 reviews available for aminolevulinic acid and Psoriasis
| Article | Year |
|---|---|
Photodynamic therapy in dermatology beyond non-melanoma cancer: An update.
Topics: Acne Vulgaris; Aminolevulinic Acid; Collagen; Humans; Photochemotherapy; Photosensitizing Agents; Po | 2017 |
Photodynamic therapy for psoriasis.
Topics: Aminolevulinic Acid; Anthracenes; Humans; Perylene; Photochemotherapy; Photosensitizing Agents; Porp | 2015 |
Photodynamic therapy: current evidence and applications in dermatology.
Topics: Acne Vulgaris; Aminolevulinic Acid; Bowen's Disease; Candidiasis; Carcinoma, Basal Cell; Humans; Ker | 2011 |
Photodynamic therapy of dermatoses other than non-melanoma skin cancer.
Topics: Administration, Topical; Aminolevulinic Acid; Humans; Keratosis; Photochemotherapy; Photosensitizing | 2005 |
Photodynamic therapy for psoriasis?
Topics: Aminolevulinic Acid; Humans; Neoplasms; Photochemotherapy; Psoriasis; Radiation-Sensitizing Agents; | 1996 |
Photodynamic therapy with systemic administration of photosensitizers in dermatology.
Topics: Aminolevulinic Acid; Bowen's Disease; Breast Neoplasms; Dermatology; Dihematoporphyrin Ether; Female | 1996 |
Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Human | 1999 |
Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer.
Topics: Acne Vulgaris; Aminolevulinic Acid; Humans; Lymphoma, T-Cell; Photochemotherapy; Photosensitizing Ag | 2002 |
Non-oncologic indications for ALA-PDT.
Topics: Aminolevulinic Acid; Humans; Lichen Sclerosus et Atrophicus; Papillomavirus Infections; Photochemoth | 2002 |
8 trials available for aminolevulinic acid and Psoriasis
| Article | Year |
|---|---|
Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques.
Topics: Administration, Oral; Aminolevulinic Acid; Apoptosis; CD3 Complex; Epidermis; Erythema; Humans; Phot | 2002 |
Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Chronic Disease; Female; Humans; Male; Middle A | 2005 |
Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Epidermis; Evaluation | 2005 |
A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis.
Topics: Adult; Aminolevulinic Acid; Cell Differentiation; Cell Proliferation; Dose Fractionation, Radiation; | 2006 |
Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Chronic Disease; Double-Blind Method; Female; H | 2006 |
Superficial blood flow following photodynamic therapy of malignant non-melanoma skin tumours measured by laser Doppler perfusion imaging.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female; | 1997 |
The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Aminolevulinic Acid; Chronic Disease; Dose-Response Relationship, Radiation; Humans; Photochemothera | 1997 |
Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Administration, Topical; Aminolevulinic Acid; Drug Administration Schedule; Female; Follow-Up Studie | 1999 |
20 other studies available for aminolevulinic acid and Psoriasis
| Article | Year |
|---|---|
Systemic ALA-PDT effectively blocks the development of psoriasis-like lesions and alleviates leucocyte infiltration in the K14-VEGF transgenic mouse.
Topics: Aminolevulinic Acid; Animals; Disease Models, Animal; Immunohistochemistry; Interferons; Interleukin | 2017 |
Photodynamic therapy with 5-aminolevulinic acid suppresses IFN-γ-induced K17 expression in HaCaT cells via MAPK pathway.
Topics: Aminolevulinic Acid; Apoptosis; Calcitriol; Caspase 3; Cell Line; Cell Survival; Extracellular Signa | 2017 |
ALA-PDT alleviates the psoriasis by inhibiting JAK signalling pathway.
Topics: Aminolevulinic Acid; Animals; Drug Evaluation, Preclinical; Female; Imiquimod; Interferon-gamma; Jan | 2019 |
Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs.
Topics: Aminolevulinic Acid; Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Female; Imiquimod; | 2015 |
Update on new drugs in dermatology.
Topics: Aminolevulinic Acid; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agent | 2016 |
Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells.
Topics: Administration, Topical; Aminolevulinic Acid; Humans; Keratosis, Actinic; Photochemotherapy; Photose | 2009 |
Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study.
Topics: Adult; Aged; Aminolevulinic Acid; Female; Humans; Lasers, Dye; Male; Middle Aged; Nail Diseases; Pho | 2009 |
Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Chemistry, Pharmaceutical; Disease Models, | 2009 |
The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Analysis of Variance; Bandages, Hydrocolloid; Bi | 2010 |
[Therapeutic effect of photodynamic treatment for psoriasis vulgaris in guinea pigs].
Topics: Acne Vulgaris; Aminolevulinic Acid; Animals; Guinea Pigs; Photochemotherapy; Photosensitizing Agents | 2011 |
Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy.
Topics: Administration, Topical; Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Ps | 2004 |
Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid.
Topics: Aminolevulinic Acid; DNA; Humans; Keratosis; Protoporphyrins; Psoriasis; Spectrometry, Fluorescence | 2005 |
Recalcitrant palmoplantar pustular psoriasis successfully treated with topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Adult; Aminolevulinic Acid; Chronic Disease; Dose-Response Relationship, Radiation; Female; Humans; | 2005 |
Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Biopsy; Cell Differentiation; Cell Proliferati | 2006 |
Topical 5-aminolaevulinic acid photodynamic therapy for intractable palmoplantar psoriasis.
Topics: Adult; Aminolevulinic Acid; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Photochemot | 2007 |
Treatment of psoriasis by topical photodynamic therapy with polychromatic light.
Topics: Administration, Topical; Aminolevulinic Acid; Anthralin; Chronic Disease; Follow-Up Studies; Humans; | 1994 |
The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy.
Topics: Administration, Topical; Aminolevulinic Acid; Dose-Response Relationship, Drug; Humans; Photochemoth | 1996 |
Købner reaction induced by photodynamic therapy using delta-aminolevulinic acid. A case report.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Photochemotherapy; Psoriasis; Recurren | 1996 |
Oral aminolevulinic acid induces protoporphyrin IX fluorescence in psoriatic plaques and peripheral blood cells.
Topics: Administration, Oral; Aminolevulinic Acid; Blood Cells; Fluorescence; Humans; Photochemotherapy; Pho | 2001 |
Chitosan/hyaluronan nanogels co-delivering methotrexate and 5-aminolevulinic acid: A combined chemo-photodynamic therapy for psoriasis.
Topics: Aminolevulinic Acid; Cell Line; Chitosan; Drug Therapy, Combination; Humans; Hyaluronic Acid; Levuli | 2022 |